Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
LSTA 
Lisata Therapeutics Inc. (LSTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/02/2026: LSTA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13
1 Year Target Price $13
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -47.21% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/02/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.29M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 3 | Beta 1.09 | 52 Weeks Range 1.81 - 4.20 | Updated Date 01/3/2026 |
52 Weeks Range 1.81 - 4.20 | Updated Date 01/3/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.13 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1876.54% |
Management Effectiveness
Return on Assets (TTM) -41.86% | Return on Equity (TTM) -72.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -5516437 | Price to Sales(TTM) 16.16 |
Enterprise Value -5516437 | Price to Sales(TTM) 16.16 | ||
Enterprise Value to Revenue 0.38 | Enterprise Value to EBITDA 0.82 | Shares Outstanding 8820733 | Shares Floating 7324472 |
Shares Outstanding 8820733 | Shares Floating 7324472 | ||
Percent Insiders 19.68 | Percent Institutions 8.38 |
Upturn AI SWOT
Lisata Therapeutics Inc.
Company Overview
History and Background
Lisata Therapeutics Inc. (NASDAQ: LSTA) is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company was founded in 2017 and has since been dedicated to advancing its proprietary platform technologies to address unmet medical needs. Significant milestones include the progression of its lead drug candidates through clinical trials and strategic partnerships.
Core Business Areas
- Preclinical and Clinical Development: Lisata's core business revolves around the research, development, and potential commercialization of its drug candidates. This involves preclinical studies, clinical trials across various phases, and regulatory submissions.
- Platform Technology: The company leverages its proprietary platform technologies designed to modulate disease pathways involved in inflammation and fibrosis. This platform forms the basis for its drug development pipeline.
Leadership and Structure
Lisata Therapeutics Inc. is led by a management team with expertise in drug development, biotechnology, and corporate strategy. The organizational structure is typical of a clinical-stage biopharmaceutical company, with dedicated departments for research and development, clinical operations, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- Description: LSTA-001 is a novel investigational drug designed to inhibit the action of galectin-1, a protein implicated in inflammatory and fibrotic processes. It is currently in clinical development for indications such as idiopathic pulmonary fibrosis (IPF) and potentially other fibrotic diseases. Competitors in this space include companies developing anti-fibrotic agents and other immunomodulatory therapies for IPF.
- Product Name 1: LSTA-001
- Description: LSTA-002 is another investigational therapy targeting specific pathways involved in inflammatory diseases. Further details on its specific indication and development stage would typically be found in company disclosures. Competitors would vary based on the specific inflammatory disease targeted.
- Product Name 2: LSTA-002
Market Dynamics
Industry Overview
Lisata Therapeutics operates within the biopharmaceutical industry, specifically focusing on the niche of inflammatory and fibrotic diseases. This sector is characterized by high R&D costs, long development timelines, significant regulatory hurdles, and a high potential for therapeutic innovation. The market for treatments for conditions like IPF is substantial and growing due to an aging population and increased diagnosis.
Positioning
Lisata Therapeutics is positioned as an emerging player in the biopharmaceutical space, aiming to disrupt the treatment landscape for inflammatory and fibrotic diseases with its novel platform and drug candidates. Its competitive advantage lies in its unique mechanism of action and the potential for broad application across various fibrotic and inflammatory conditions.
Total Addressable Market (TAM)
The TAM for treatments for inflammatory and fibrotic diseases, particularly conditions like idiopathic pulmonary fibrosis, is in the billions of dollars globally and is projected to grow. Lisata Therapeutics is positioned to capture a segment of this market with its investigational therapies, contingent on successful clinical development and regulatory approval.
Upturn SWOT Analysis
Strengths
- Proprietary platform technology with potential for broad application.
- Experienced management team with a focus on drug development.
- Pipeline of novel drug candidates targeting significant unmet medical needs.
Weaknesses
- Clinical-stage company with no approved products, leading to reliance on future success.
- High dependence on external funding for continued research and development.
- Limited product diversification currently.
Opportunities
- Potential for significant market penetration if drug candidates are successful.
- Strategic partnerships and collaborations to accelerate development and commercialization.
- Expansion into other inflammatory and fibrotic indications.
- Advancements in scientific understanding of disease mechanisms.
Threats
- Clinical trial failures or delays, leading to significant setbacks.
- Intense competition from established pharmaceutical companies and other biotechs.
- Regulatory hurdles and lengthy approval processes.
- Changes in healthcare policy and reimbursement.
Competitors and Market Share
Key Competitors
- Prometheus Biosciences, Inc. (PRMB)
- Veru Inc. (VERU)
- Kadmon Holdings, Inc. (KDMN) - (Acquired by Sanofi in 2022)
- Gilead Sciences, Inc. (GILD) - (for certain fibrosis indications)
- Boehringer Ingelheim (Privately held)
- AbbVie Inc. (ABBV) - (for certain inflammatory indications)
Competitive Landscape
Lisata Therapeutics faces a competitive landscape with both smaller clinical-stage biotechs and larger pharmaceutical companies developing therapies for inflammatory and fibrotic diseases. Its advantages lie in its specific scientific approach and novel targets. However, larger competitors often have greater resources for R&D, clinical development, and marketing, as well as established market presence and distribution networks.
Growth Trajectory and Initiatives
Historical Growth: Historically, Lisata Therapeutics' growth has been characterized by its progression through research and preclinical stages to clinical development. This has involved significant investment in R&D and strategic fundraising to support its operations.
Future Projections: Future growth projections for Lisata Therapeutics are contingent on the successful outcomes of its ongoing clinical trials and subsequent regulatory approvals. Analyst estimates would focus on the potential market size of its target indications and the projected timeline to commercialization. Aggressive growth is anticipated if its lead candidates prove effective.
Recent Initiatives: Recent initiatives likely include the advancement of its lead drug candidates into later-stage clinical trials, potential licensing or partnership agreements, and ongoing efforts to secure additional funding to support its development pipeline.
Summary
Lisata Therapeutics Inc. is a clinical-stage biopharmaceutical company with promising novel drug candidates for inflammatory and fibrotic diseases. Its proprietary platform offers a potential competitive edge. However, as a pre-revenue company, it faces significant risks associated with clinical trial outcomes, regulatory approvals, and the need for substantial funding. Continued progress in clinical development and successful fundraising are critical for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Lisata Therapeutics Inc. official investor relations website
- SEC filings (10-K, 10-Q)
- Financial news and analysis platforms (e.g., Yahoo Finance, Bloomberg)
- Industry reports on biopharmaceutical and fibrosis markets
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Market share data for clinical-stage companies is often estimated or based on specific therapeutic areas of focus.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lisata Therapeutics Inc.
Exchange NASDAQ | Headquaters Basking Ridge, NJ, United States | ||
IPO Launch date 1999-03-01 | President, CEO & Director Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 26 | Website https://www.lisata.com |
Full time employees 26 | Website https://www.lisata.com | ||
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.